XOMA Corp (XOMAP) 8.625% Series A Cumulative Perpetual Pref

Sell:$25.19Buy:$27.00$0.17 (0.65%)

Prices delayed by at least 15 minutes
Sell:$25.19
Buy:$27.00
Change:$0.17 (0.65%)
Deal now
Prices delayed by at least 15 minutes
Sell:$25.19
Buy:$27.00
Change:$0.17 (0.65%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Key people

Click to see more

Key facts

  • EPIC
    XOMA
  • Location
    United States
  • Sector
    Financial
  • Industry
    Misc. Financial Services
  • ISIN
    US98419J3059
  • Market cap
    $480.12m
  • Employees
    13
  • Shares in issue
    12.09m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.